 [1m([0morchestrator-aplastic anemia-CAPTOPRIL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes CAPTOPRIL increase or decrease the risk of aplastic anemia?[0m
 [1m([0morchestrator-aplastic anemia-CAPTOPRIL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-aplastic anemia-CAPTOPRIL[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-aplastic anemia-CAPTOPRIL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does CAPTOPRIL increase or decrease the risk of aplastic anemia?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-aplastic anemia-CAPTOPRIL[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes CAPTOPRIL increase or decrease the risk of aplastic anemia?[0m
 [1m([0morchestrator-aplastic anemia-CAPTOPRIL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-aplastic anemia-CAPTOPRIL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-aplastic anemia-CAPTOPRIL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes CAPTOPRIL increase or decrease the risk of aplastic anemia?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does CAPTOPRIL increase or decrease the risk of aplastic anemia?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"CAPTOPRIL"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: CAPTOPRIL: warnings: Swelling confined to the face, mucous membranes of the mouth, lips and extremities has usually resolved with discontinuation of treatment; some cases required medical [0m
[31mtherapy. [0m[1;31m([0m[31mSee PRECAUTIONS: Information for Patients and ADVERSE REACTIONS: Captopril .[0m[1;31m)[0m[31m Intestinal Angioedema : Intestinal angioedema has been reported in patients treated with ACE inhibitors. These [0m
[31mpatients presented with abdominal pain [0m[1;31m([0m[31mwith or without nausea or vomiting[0m[1;31m)[0m[31m; in some cases there was no prior history of facial angioedema and C-[0m[1;31m1[0m[31m esterase levels were normal. The angioedema was [0m
[31mdiagnosed by procedures including abdominal CT scan or ultrasound, or at surgery, and symptoms resolved after stopping the ACE inhibitor. Intestinal angioedema should be included in the differential [0m
[31mdiagnosis of patients on ACE inhibitors presenting with abdominal pain. CAPTOPRIL: warnings: Anaphylactoid Reactions During Desensitization : Two patients undergoing desensitizing treatment with [0m
[31mhymenoptera venom while receiving ACE inhibitors sustained life-threatening anaphylactoid reactions. In the same patients, these reactions were avoided when ACE inhibitors were temporarily withheld, [0m
[31mbut they reappeared upon inadvertent rechallenge. Anaphylactoid Reactions During Membrane Exposure : Anaphylactoid reactions have been reported in patients dialyzed with high-flux membranes and [0m
[31mtreated concomitantly with an ACE inhibitor. Anaphylactoid reactions have also been reported in patients undergoing low-density lipoprotein apheresis with dextran sulfate absorption. [0m
[31mNeutropenia/Agranulocytosis : Neutropenia [0m[1;31m([0m[31m< [0m[1;31m1000[0m[31m/mm [0m[1;31m3[0m[31m [0m[1;31m)[0m[31m with myeloid hypoplasia has resulted from use of captopril. CAPTOPRIL: warnings: About half of the neutropenic patients developed systemic or [0m
[31moral cavity infections or other features of the syndrome of agranulocytosis. The risk of neutropenia is dependent on the clinical status of the patient: In clinical trials in patients with [0m
[31mhypertension who have normal renal function [0m[1;31m([0m[31mserum creatinine less than [0m[1;31m1.6[0m[31m mg/dL and no collagen vascular disease[0m[1;31m)[0m[31m, neutropenia has been seen in one patient out of over [0m[1;31m8[0m[31m,[0m[1;31m600[0m[31m exposed. In patients [0m
[31mwith some degree of renal failure [0m[1;31m([0m[31mserum creatinine at least [0m[1;31m1.6[0m[31m mg/dL[0m[1;31m)[0m[31m but no collagen vascular disease, the risk of neutropenia in clinical trials was about [0m[1;31m1[0m[31m per [0m[1;31m500[0m[31m, a frequency over [0m[1;31m15[0m[31m times that[0m
[31mfor uncomplicated hypertension. Daily doses of captopril were relatively high in these patients, particularly in view of their diminished renal function. CAPTOPRIL: warnings: In foreign marketing [0m
[31mexperience in patients with renal failure, use of allopurinol concomitantly with captopril has been associated with neutropenia but this association has not appeared in U.S. reports. In patients with [0m
[31mcollagen vascular diseases [0m[1;31m([0m[31me.g., systemic lupus erythematosus, scleroderma[0m[1;31m)[0m[31m and impaired renal function, neutropenia occurred in [0m[1;31m3.7[0m[31m percent of patients in clinical trials. While none of the over [0m[1;31m750[0m
[31mpatients in formal clinical trials of heart failure developed neutropenia, it has occurred during the subsequent clinical experience. About half of the reported cases had serum creatinine â‰¥ [0m[1;31m1.6[0m[31m mg/dL [0m
[31mand more than [0m[1;31m75[0m[31m percent were in patients also receiving procainamide. In heart failure, it appears that the same risk factors for neutropenia are present. The neutropenia has usually been detected [0m
[31mwithin three months after captopril was started. CAPTOPRIL: warnings: Bone marrow examinations in patients with neutropenia consistently showed myeloid hypoplasia, frequently accompanied by erythroid [0m
[31mhypoplasia and decreased numbers of megakaryocytes [0m[1;31m([0m[31me.g., hypoplastic bone marrow and pancytopenia[0m[1;31m)[0m[31m; anemia and thrombocytopenia were sometimes seen. In general, neutrophils returned to normal in [0m
[31mabout two weeks after captopril was discontinued, and serious infections were limited to clinically complex patients. About [0m[1;31m13[0m[31m percent of the cases of neutropenia have ended fatally, but almost all [0m
[31mfatalities were in patients with serious illness, having collagen vascular disease, renal failure, heart failure or immunosuppressant therapy, or a combination of these complicating factors. [0m
[31mEvaluation of the hypertensive or heart failure patient should always include assessment of renal function. CAPTOPRIL: warnings: If captopril is used in patients with impaired renal function, white [0m
[31mblood cell and differential counts should be evaluated prior to starting treatment and at approximately two-week intervals for about three months, then periodically. In patients with collagen vascular[0m
[31mdisease or who are exposed to other drugs known to affect the white cells or immune response, particularly when there is impaired renal function, captopril should be used only after an assessment of [0m
[31mbenefit and risk, and then with caution. All patients treated with captopril should be told to report any signs of infection [0m[1;31m([0m[31me.g., sore throat, fever[0m[1;31m)[0m[31m. If infection is suspected, white cell counts [0m
[31mshould be performed without delay. Since discontinuation of captopril and other drugs has generally led to prompt return of the white count to normal, upon confirmation of neutropenia [0m[1;31m([0m[31mneutrophil [0m
[31mcount < [0m[1;31m1000[0m[31m/mm [0m[1;31m3[0m[31m [0m[1;31m)[0m[31m the physician should withdraw captopril and closely follow the patientâ€™s course. CAPTOPRIL: warnings: Proteinuria : Total urinary proteins greater than [0m[1;31m1[0m[31m g per day were seen in [0m
[31mabout [0m[1;31m0.7[0m[31m percent of patients receiving captopril. About [0m[1;31m90[0m[31m percent of affected patients had evidence of prior renal disease or received relatively high doses of captopril [0m[1;31m([0m[31min excess of [0m[1;31m150[0m[31m mg/day[0m[1;31m)[0m[31m, [0m
[31mor both. The nephrotic syndrome occurred in about one-fifth of proteinuric patients. In most cases, proteinuria subsided or cleared within six months whether or not captopril was continued. Parameters[0m
[31mof renal function, such as BUN and creatinine, were seldom altered in the patients with proteinuria. Hypotension : Excessive hypotension was rarely seen in hypertensive patients but is a possible [0m
[31mconsequence of captopril use in salt/volume depleted persons [0m[1;31m([0m[31msuch as those treated vigorously with diuretics[0m[1;31m)[0m[31m, patients with heart failure or those patients undergoing renal dialysis. [0m[1;31m([0m[31mSee [0m
[31mPRECAUTIONS: Drug Interactions .         [0m
[31mSOUR[0m[1;31mCE:CA[0m[31mPTOPRIL label[0m


[31mCONTENT: CAPTOPRIL: adverse_reactions: ADVERSE REACTIONS Captopril : Reported incidences are based on clinical trials involving approximately [0m[1;31m7000[0m[31m patients. Renal : About one of [0m[1;31m100[0m[31m patients developed[0m
[31mproteinuria [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. Each of the following has been reported in approximately [0m[1;31m1[0m[31m to [0m[1;31m2[0m[31m of [0m[1;31m1000[0m[31m patients and are of uncertain relationship to drug use: renal insufficiency, renal failure, [0m
[31mnephrotic syndrome, polyuria, oliguria, and urinary frequency. Hematologic : Neutropenia/agranulocytosis has occurred [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. Cases of anemia, thrombocytopenia, and pancytopenia have been [0m
[31mreported. Dermatologic : Rash, often with pruritus, and sometimes with fever, arthralgia, and eosinophilia, occurred in about [0m[1;31m4[0m[31m to [0m[1;31m7[0m[31m [0m[1;31m([0m[31mdepending on renal status and dose[0m[1;31m)[0m[31m of [0m[1;31m100[0m[31m patients, usually [0m
[31mduring the first four weeks of therapy. CAPTOPRIL: adverse_reactions: It is usually maculopapular, and rarely urticarial. The rash is usually mild and disappears within a few days of dosage reduction,[0m
[31mshort-term treatment with an antihistaminic agent, and/or discontinuing therapy; remission may occur even if captopril is continued. Pruritus, without rash, occurs in about [0m[1;31m2[0m[31m of [0m[1;31m100[0m[31m patients. Between [0m
[1;31m7[0m[31m and [0m[1;31m10[0m[31m percent of patients with skin rash have shown eosinophilia and/or positive ANA titers. A reversible associated pemphigoid-like lesion, and photosensitivity, have also been reported. Flushing [0m
[31mor pallor has been reported in [0m[1;31m2[0m[31m to [0m[1;31m5[0m[31m of [0m[1;31m1000[0m[31m patients. Cardiovascular : Hypotension may occur; see WARNINGS and PRECAUTIONS [0m[1;31m([0m[31mDrug Interactions[0m[1;31m)[0m[31m for discussion of hypotension with captopril therapy. [0m
[31mTachycardia, chest pain, and palpitations have each been observed in approximately [0m[1;31m1[0m[31m of [0m[1;31m100[0m[31m patients. CAPTOPRIL: adverse_reactions: Angina pectoris, myocardial infarction, Raynaudâ€™s syndrome, and [0m
[31mcongestive heart failure have each occurred in [0m[1;31m2[0m[31m to [0m[1;31m3[0m[31m of [0m[1;31m1000[0m[31m patients. Dysgeusia : Approximately [0m[1;31m2[0m[31m to [0m[1;31m4[0m[31m [0m[1;31m([0m[31mdepending on renal status and dose[0m[1;31m)[0m[31m of [0m[1;31m100[0m[31m patients developed a diminution or loss of taste [0m
[31mperception. Taste impairment is reversible and usually self-limited [0m[1;31m([0m[1;31m2[0m[31m to [0m[1;31m3[0m[31m months[0m[1;31m)[0m[31m even with continued drug administration. Weight loss may be associated with the loss of taste. Angioedema : [0m
[31mAngioedema involving the extremities, face, lips, mucous membranes, tongue, glottis or larynx has been reported in approximately one in [0m[1;31m1000[0m[31m patients. Angioedema involving the upper airways has caused[0m
[31mfatal airway obstruction. [0m[1;31m([0m[31mSee WARNINGS: Captopril: Head and Neck Angioedema and Intestinal Angioedema and PRECAUTIONS: Information for Patients [0m[1;31m)[0m[31m. CAPTOPRIL: adverse_reactions: Cough : Cough has been[0m
[31mreported in [0m[1;31m0.5[0m[31m to [0m[1;31m2[0m[31m% of patients treated with captopril in clinical trials [0m[1;31m([0m[31msee PRECAUTIONS: General: Captopril: Cough [0m[1;31m)[0m[31m. The following have been reported in about [0m[1;31m0.5[0m[31m to [0m[1;31m2[0m[31m percent of patients but [0m
[31mdid not appear at increased frequency compared to placebo or other treatments used in controlled trials: gastric irritation, abdominal pain, nausea, vomiting, diarrhea, anorexia, constipation, [0m
[31maphthous ulcers, peptic ulcer, dizziness, headache, malaise, fatigue, insomnia, dry mouth, dyspnea, alopecia, paresthesias. Other clinical adverse effects reported since the drug was marketed are [0m
[31mlisted below by body system. In this setting, an incidence or causal relationship cannot be accurately determined. CAPTOPRIL: adverse_reactions: Body as a Whole : Anaphylactoid reactions [0m[1;31m([0m[31msee [0m
[31mWARNINGS: Captopril: Anaphylactoid and Possibly Related Reactions and PRECAUTIONS: Hemodialysis [0m[1;31m)[0m[31m. General : asthenia, gynecomastia. Cardiovascular : cardiac arrest, cerebrovascular [0m
[31maccident/insufficiency, rhythm disturbances, orthostatic hypotension, syncope. Dermatologic : bullous pemphigus, erythema multiforme [0m[1;31m([0m[31mincluding Stevens-Johnson syndrome[0m[1;31m)[0m[31m, exfoliative dermatitis. [0m
[31mGastrointestinal : pancreatitis, glossitis, dyspepsia. Hematologic : anemia, including aplastic and hemolytic. Hepatobiliary : jaundice, hepatitis, including rare cases of necrosis, cholestasis. [0m
[31mMetabolic : symptomatic hyponatremia. Musculoskeletal : myalgia, myasthenia. CAPTOPRIL: adverse_reactions: Nervous/Psychiatric : ataxia, confusion, depression, nervousness, somnolence. Respiratory : [0m
[31mbronchospasm, eosinophilic pneumonitis, rhinitis. Special Senses : blurred vision. Urogenital : impotence. As with other ACE inhibitors, a syndrome has been reported which may include: fever, myalgia,[0m
[31marthralgia, interstitial nephritis, vasculitis, rash or other dermatologic manifestations, eosinophilia and an elevated ESR. Fetal/Neonatal Morbidity and Mortality: See WARNINGS: Captopril: [0m
[31mFetal/Neonatal Morbidity and Mortality . Hydrochlorothiazide : Gastrointestinal System : anorexia, gastric irritation, nausea, vomiting, cramping, diarrhea, constipation, jaundice [0m[1;31m([0m[31mintrahepatic [0m
[31mcholestatic jaundice[0m[1;31m)[0m[31m, pancreatitis, and sialadenitis. CAPTOPRIL: adverse_reactions: Central Nervous System : dizziness, vertigo, paresthesias, headache, and xanthopsia. Hematologic : leukopenia, [0m
[31magranulocytosis, thrombocytopenia, aplastic anemia, and hemolytic anemia. Cardiovascular : orthostatic hypotension. Hypersensitivity : purpura, photosensitivity, rash, urticaria, necrotizing angiitis [0m
[1;31m([0m[31mvasculitis; cutaneous vasculitis[0m[1;31m)[0m[31m, fever, respiratory distress including pneumonitis, and anaphylactic reactions. Other : hyperglycemia, glycosuria, hyperuricemia, muscle spasm, weakness, [0m
[31mrestlessness, and transient blurred vision. Whenever adverse reactions are moderate or severe, thiazide dosage should be reduced or therapy withdrawn. CAPTOPRIL: adverse_reactions: Altered Laboratory [0m
[31mFindings: Serum Electrolytes : Hyperkalemia: small increases in serum potassium, especially in patients with renal impairment [0m[1;31m([0m[31msee PRECAUTIONS: Captopril [0m[1;31m)[0m[31m. Hyponatremia : particularly in patients [0m
[31mreceiving a low sodium diet or concomitant diuretics. BUN/Serum Creatinine : Transient elevations of BUN or serum creatinine especially in volume or salt depleted patients or those with renovascular [0m
[31mhypertension may occur. Rapid reduction of longstanding or markedly elevated blood pressure can result in decreases in the glomerular filtration rate and, in turn, lead to increases in BUN or serum [0m
[31mcreatinine. Hematologic : A positive ANA has been reported. Liver Function Tests : Elevations of liver transaminases, alkaline phosphatase, and serum bilirubin have occurred. CAPTOPRIL: [0m
[31madverse_reactions: Postmarketing Experience : Non-melanoma Skin Cancer : Hydrochlorothiazide is associated with an increased risk of non-melanoma skin cancer. In a study conducted in the Sentinel [0m
[31mSystem, increased risk was predominantly for squamous cell carcinoma [0m[1;31m([0m[31mSCC[0m[1;31m)[0m[31m and in white patients taking large cumulative doses. The increased risk for SCC in the overall population was approximately [0m[1;31m1[0m
[31madditional case per [0m[1;31m16[0m[31m,[0m[1;31m000[0m[31m patients per year, and for white patients taking a cumulative dose of â‰¥ [0m[1;31m50[0m[31m,[0m[1;31m000[0m[31m mg the risk increase was approximately [0m[1;31m1[0m[31m additional SCC case for every [0m[1;31m6[0m[31m,[0m[1;31m700[0m[31m patients per [0m
[31myear. To report SUSPECTED ADVERSE REACTIONS, contact Rising Pharma Holdings, Inc. at [0m[1;31m1[0m[31m-[0m[1;31m844[0m[31m- [0m[1;31m874[0m[31m-[0m[1;31m7464[0m[31m or FDA at [0m[1;31m1[0m[31m-[0m[1;31m800[0m[31m-FDA-[0m[1;31m1088[0m[31m or www.fda.gov/medwatch.         [0m
[31mSOUR[0m[1;31mCE:CA[0m[31mPTOPRIL label[0m


[31mCONTENT: CAPTOPRIL: openfda: spl_id         [0m
[31mSOUR[0m[1;31mCE:CA[0m[31mPTOPRIL label[0m


[31mCONTENT: CAPTOPRIL: openfda: pharm_class_pe         [0m
[31mSOUR[0m[1;31mCE:CA[0m[31mPTOPRIL label[0m


[31mCONTENT: CAPTOPRIL: openfda: package_ndc         [0m
[31mSOUR[0m[1;31mCE:CA[0m[31mPTOPRIL label[0m


[31mCONTENT: CAPTOPRIL: openfda: pharm_class_cs         [0m
[31mSOUR[0m[1;31mCE:CA[0m[31mPTOPRIL label[0m


[31mCONTENT: CAPTOPRIL: carcinogenesis_and_mutagenesis_and_impairment_of_fertility: Hydrochlorothiazide : Two-year feeding studies in mice and rats conducted under the auspices of the National Toxicology [0m
[31mProgram [0m[1;31m([0m[31mNTP[0m[1;31m)[0m[31m uncovered no evidence of a carcinogenic potential of hydrochlorothiazide in female mice [0m[1;31m([0m[31mat doses of up to approximately [0m[1;31m600[0m[31m mg/kg/day[0m[1;31m)[0m[31m or in male and female rats [0m[1;31m([0m[31mat doses of up to [0m
[31mapproximately [0m[1;31m100[0m[31m mg/kg/day[0m[1;31m)[0m[31m. The NTP, however, found equivocal evidence for hepatocarcinogenicity in male mice. Hydrochlorothiazide was not genotoxic in in vitro assays using strains TA [0m[1;31m98[0m[31m, TA [0m[1;31m100[0m[31m, [0m
[31mTA [0m[1;31m1535[0m[31m, TA [0m[1;31m1537[0m[31m and TA [0m[1;31m1538[0m[31m of Salmonella typhimurium [0m[1;31m([0m[31mAmes assay[0m[1;31m)[0m[31m and in the Chinese Hamster Ovary [0m[1;31m([0m[31mCHO[0m[1;31m)[0m[31m test for chromosomal aberrations, or in vivo assays using mouse germinal cell chromosomes, [0m
[31mChinese hamster bone marrow chromosomes, and the Drosophilia sex linked recessive lethal trait gene. CAPTOPRIL: precautions: Positive test results were obtained only in the in vitro CHO Sister [0m
[31mChromatid Exchange [0m[1;31m([0m[31mclastogenicity[0m[1;31m)[0m[31m and in the Mouse Lymphoma Cell [0m[1;31m([0m[31mmutagenicity[0m[1;31m)[0m[31m assays, using concentrations of hydrochlorothiazide from [0m[1;31m43[0m[31m to [0m[1;31m1300[0m[31m mcg/mL, and in the Aspergillus nidulans [0m
[31mnon-disjunction assay at an unspecified concentration. Hydrochlorothiazide had no adverse effects on the fertility of mice and rats of either sex in studies wherein these species were exposed, via [0m
[31mtheir diet, to doses of up to [0m[1;31m100[0m[31m and [0m[1;31m4[0m[31m mg/kg, respectively, prior to conception and throughout gestation. Animal Toxicology Captopril : Chronic oral toxicity studies were conducted in rats [0m[1;31m([0m[1;31m2[0m[31m years[0m[1;31m)[0m[31m,[0m
[31mdogs [0m[1;31m([0m[1;31m47[0m[31m weeks; [0m[1;31m1[0m[31m year[0m[1;31m)[0m[31m, mice [0m[1;31m([0m[1;31m2[0m[31m years[0m[1;31m)[0m[31m, and monkeys [0m[1;31m([0m[1;31m1[0m[31m year[0m[1;31m)[0m[31m. Significant drug-related toxicity included effects on hematopoiesis, renal toxicity, erosion/ulceration of the stomach, and variation of [0m
[31mretinal blood vessels. CAPTOPRIL: precautions: Reductions in hemoglobin and/or hematocrit values were seen in mice, rats, and monkeys at doses [0m[1;31m50[0m[31m to [0m[1;31m150[0m[31m times the maximum recommended human dose [0m
[1;31m([0m[31mMRHD[0m[1;31m)[0m[31m. Anemia, leukopenia, thrombocytopenia, and bone marrow suppression occurred in dogs at doses [0m[1;31m8[0m[31m to [0m[1;31m30[0m[31m times MRHD. The reductions in hemoglobin and hematocrit values in rats and mice were only [0m
[31msignificant at [0m[1;31m1[0m[31m year and returned to normal with continued dosing by the end of the study. Marked anemia was seen at all dose levels [0m[1;31m([0m[1;31m8[0m[31m to [0m[1;31m30[0m[31m times MRHD[0m[1;31m)[0m[31m in dogs, whereas moderate to marked [0m
[31mleukopenia was noted only at [0m[1;31m15[0m[31m and [0m[1;31m30[0m[31m times MRHD and thrombocytopenia at [0m[1;31m30[0m[31m times MRHD. The anemia could be reversed upon discontinuation of dosing. CAPTOPRIL: precautions: Bone marrow suppression [0m
[31moccurred to a varying degree, being associated only with dogs that died or were sacrificed in a moribund condition in the [0m[1;31m1[0m[31m year study. However, in the [0m[1;31m47[0m[31m-week study at a dose [0m[1;31m30[0m[31m times MRHD, bone [0m
[31mmarrow suppression was found to be reversible upon continued drug administration. Captopril caused hyperplasia of the juxtaglomerular apparatus of the kidneys at doses [0m[1;31m7[0m[31m to [0m[1;31m200[0m[31m times the MRHD in rats [0m
[31mand mice, at [0m[1;31m20[0m[31m to [0m[1;31m60[0m[31m times MRHD in monkeys, and at [0m[1;31m30[0m[31m times the MRHD in dogs. Gastric erosions/ulcerations were increased in incidence at [0m[1;31m20[0m[31m and [0m[1;31m200[0m[31m times MRHD in male rats and at [0m[1;31m30[0m[31m and [0m[1;31m65[0m[31m times [0m
[31mMRHD in dogs and monkeys, respectively. Rabbits developed gastric and intestinal ulcers when given oral doses approximately [0m[1;31m30[0m[31m times MRHD for only five to seven days. CAPTOPRIL: precautions: In the [0m
[31mtwo-year rat study, irreversible and progressive variations in the caliber of retinal vessels [0m[1;31m([0m[31mfocal sacculations and constrictions[0m[1;31m)[0m[31m occurred at all dose levels [0m[1;31m([0m[1;31m7[0m[31m to [0m[1;31m200[0m[31m times MRHD[0m[1;31m)[0m[31m in a dose-related[0m
[31mfashion. The effect was first observed in the [0m[1;31m88[0m[31m th week of dosing, with a progressively increased incidence thereafter, even after cessation of dosing. Pregnancy Categories C [0m[1;31m([0m[31mfirst trimester[0m[1;31m)[0m[31m and D [0m
[1;31m([0m[31msecond and third trimesters[0m[1;31m)[0m[31m: See WARNINGS: Captopril: Fetal/Neonatal Morbidity and Mortality . Pregnancy: Nonteratogenic Effects: Hydrochlorothiazide : Thiazides cross the placental barrier and [0m
[31mappear in cord blood. The use of thiazides in pregnant women requires that the anticipated benefit be weighed against possible hazards to the fetus. These hazards include fetal or neonatal jaundice, [0m
[31mthrombocytopenia, and possibly other adverse reactions which have occurred in the adult.         [0m
[31mSOUR[0m[1;31mCE:CA[0m[31mPTOPRIL label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: CAPTOPRIL has been reported to cause hematologic adverse reactions, including cases of anemia, thrombocytopenia, and pancytopenia. Aplastic anemia is also listed among the hematologic adverse [0m
[32mreactions reported postmarketing, which means it has been observed in patients after the drug was approved for use. However, the incidence or causal relationship of aplastic anemia to CAPTOPRIL use [0m
[32mcannot be accurately determined from the available information.[0m

[32mSOURCE: CAPTOPRIL label[0m
[32mEXTRACT_START_END: Hematologic : anemia, including aplastic [0m[32m...[0m[32m causal relationship cannot be accurately determined.[0m
*[1m([0morchestrator-aplastic anemia-CAPTOPRIL[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: CAPTOPRIL has been reported to cause hematologic adverse [0m
[34mreactions, including cases of anemia, thrombocytopenia, and pancytopenia. Aplastic anemia is also listed among the hematologic adverse reactions reported postmarketing, which means it has been [0m
[34mobserved in patients after the drug was approved for use. However, the incidence or causal relationship of aplastic anemia to CAPTOPRIL use cannot be accurately determined from the available [0m
[34minformation.[0m

[34mSOURCE: CAPTOPRIL label[0m
[34mEXTRACT_START_END: Hematologic : anemia, including aplastic [0m[34m...[0m[34m causal relationship cannot be accurately determined.[0m
 [1m([0morchestrator-aplastic anemia-CAPTOPRIL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-aplastic anemia-CAPTOPRIL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-aplastic anemia-CAPTOPRIL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does CAPTOPRIL increase or decrease the risk of aplastic anemia?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether CAPTOPRIL increases or decreases the risk of aplastic anemia."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that CAPTOPRIL has been reported to cause hematologic adverse reactions, including cases of anemia, thrombocytopenia, and pancytopenia. Aplastic anemia is listed among the [0m
[32mhematologic adverse reactions reported postmarketing."[0m[32m,[0m
[32m      [0m[32m"The incidence or causal relationship of aplastic anemia to CAPTOPRIL use cannot be accurately determined from the available information."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"CAPTOPRIL has been associated with hematologic adverse reactions, including aplastic anemia, in postmarketing reports. However, the incidence or causal relationship of aplastic anemia [0m
[32mto CAPTOPRIL use cannot be accurately determined. Therefore, it is not definitively known whether CAPTOPRIL increases or decreases the risk of aplastic anemia."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-aplastic anemia-CAPTOPRIL[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-aplastic anemia-CAPTOPRIL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-aplastic anemia-CAPTOPRIL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-aplastic anemia-CAPTOPRIL[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does CAPTOPRIL increase or decrease the risk of aplastic anemia?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether CAPTOPRIL increases or decreases the risk of aplastic anemia."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that CAPTOPRIL has been reported to cause hematologic adverse reactions, including cases of anemia, thrombocytopenia, and pancytopenia. Aplastic anemia is listed among the [0m
[34mhematologic adverse reactions reported postmarketing."[0m[34m,[0m
[34m      [0m[34m"The incidence or causal relationship of aplastic anemia to CAPTOPRIL use cannot be accurately determined from the available information."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"CAPTOPRIL has been associated with hematologic adverse reactions, including aplastic anemia, in postmarketing reports. However, the incidence or causal relationship of aplastic anemia [0m
[34mto CAPTOPRIL use cannot be accurately determined. Therefore, it is not definitively known whether CAPTOPRIL increases or decreases the risk of aplastic anemia."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does CAPTOPRIL increase or decrease the risk of aplastic anemia?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether CAPTOPRIL increases or decreases the risk of aplastic anemia.[0m
[1;31m2[0m[31m. FDAHandler responded that CAPTOPRIL has been reported to cause hematologic adverse reactions, including cases of anemia, thrombocytopenia, and pancytopenia. Aplastic anemia is listed among the [0m
[31mhematologic adverse reactions reported postmarketing.[0m
[1;31m3[0m[31m. The incidence or causal relationship of aplastic anemia to CAPTOPRIL use cannot be accurately determined from the available information.[0m
[31m        -----[0m
[31m        Final answer: CAPTOPRIL has been associated with hematologic adverse reactions, including aplastic anemia, in postmarketing reports. However, the incidence or causal relationship of aplastic [0m
[31manemia to CAPTOPRIL use cannot be accurately determined. Therefore, it is not definitively known whether CAPTOPRIL increases or decreases the risk of aplastic anemia.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-aplastic anemia-CAPTOPRIL[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-aplastic anemia-CAPTOPRIL[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-aplastic anemia-CAPTOPRIL[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-aplastic anemia-CAPTOPRIL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-aplastic anemia-CAPTOPRIL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mCAPTOPRIL has been associated with hematologic adverse reactions, including aplastic anemia, in postmarketing reports. However, the incidence or causal relationship of aplastic anemia to CAPTOPRIL use[0m
[32mcannot be accurately determined. Therefore, it is not definitively known whether CAPTOPRIL increases or decreases the risk of aplastic anemia.[0m
